^
    Evidence Level:
    Sensitive: A1 - Approval

    [KRAS G12C-Non Small Cell Lung Cancer-adagrasib]

    Source:
    FDA
    Test:

    therascreen® KRAS RGQ PCR Kit, Resolution ctDx FIRST Assay

    Published date:
    12/12/2022
    Excerpt:
    KRAZATI is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.
    Evidence Level:
    Sensitive: A1 - Approval

    [KRAS G12C-Non Small Cell Lung Cancer-sotorasib]

    Source:
    FDA
    Test:

    Guardant360® CDx, therascreen® KRAS RGQ PCR Kit

    Published date:
    05/28/2021
    Excerpt:
    LUMAKRAS is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
    Evidence Level:
    Sensitive: B - Late Trials

    [KRAS G12V-Colorectal Cancer-panitumumab]

    Source:
    ScienceDirect
    Test:

    therascreen® KRAS RGQ PCR Kit

    Title:
    PD-0025 Evaluation of Codon 12 and 13 KRAS Mutations as Biomarkers of Response to Panitumumab in Patients with Metastatic Colorectal Cancer
    Excerpt:
    MT KRAS alleles were significantly associated with outcomes by interaction testing: in the panitumumab + FOLFOX4 arm of study 20050203 G12V was favorably and G13D was unfavorably associated with OS.
    Secondary therapy:
    FOLFOX4
    DOI:
    10.1016/S0923-7534(20)30001-6
    Evidence Level:
    Resistant: B - Late Trials

    [KRAS G12A-Colorectal Cancer-panitumumab]

    Source:
    ScienceDirect
    Test:

    therascreen® KRAS RGQ PCR Kit

    Title:
    PD-0025 Evaluation of Codon 12 and 13 KRAS Mutations as Biomarkers of Response to Panitumumab in Patients with Metastatic Colorectal Cancer
    Excerpt:
    Finally, pooled analysis of all 3 trials suggested that only the G12A KRAS allele was significantly associated with a negative treatment effect on OS....The results from this retrospective analysis of three phase 3 trials indicate that patients with MT KRAS codon 12 or 13 mCRC tumors are unlikely to benefit from panitumumab therapy.
    DOI:
    10.1016/S0923-7534(20)30001-6
    Evidence Level:
    Resistant: B - Late Trials

    [KRAS G13D-Colorectal Cancer-panitumumab]

    Source:
    ScienceDirect
    Test:

    therascreen® KRAS RGQ PCR Kit

    Title:
    PD-0025 Evaluation of Codon 12 and 13 KRAS Mutations as Biomarkers of Response to Panitumumab in Patients with Metastatic Colorectal Cancer
    Excerpt:
    Only two individual MT KRAS alleles were significantly associated with outcomes by interaction testing: in the panitumumab + FOLFOX4 arm of study 20050203 G12V was favorably and G13D was unfavorably associated with OS....The results from this retrospective analysis of three phase 3 trials indicate that patients with MT KRAS codon 12 or 13 mCRC tumors are unlikely to benefit from panitumumab therapy.
    Secondary therapy:
    FOLFOX4
    DOI:
    10.1016/S0923-7534(20)30001-6
    Trial ID:
    PRIME